Brokerages Set Fractyl Health, Inc. (NASDAQ:GUTS) Target Price at $5.12

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have earned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $5.12.

A number of brokerages have weighed in on GUTS. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a report on Thursday, June 4th. Canaccord Genuity Group reiterated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, March 26th. Weiss Ratings raised Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Craig Hallum assumed coverage on Fractyl Health in a report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price objective on the stock. Finally, Wall Street Zen raised Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th.

Insider Buying and Selling

In other Fractyl Health news, Director Ian Sheffield acquired 35,000 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was bought at an average cost of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the purchase, the director directly owned 35,000 shares in the company, valued at $25,550. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William Bradley acquired 68,493 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was acquired at an average cost of $0.73 per share, with a total value of $49,999.89. Following the transaction, the director directly owned 84,622 shares of the company’s stock, valued at approximately $61,774.06. This represents a 424.66% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 171,493 shares of company stock valued at $127,150. Corporate insiders own 8.52% of the company’s stock.

Institutional Trading of Fractyl Health

A number of institutional investors have recently added to or reduced their stakes in GUTS. Jane Street Group LLC acquired a new position in shares of Fractyl Health during the second quarter worth about $31,000. FNY Investment Advisers LLC purchased a new stake in shares of Fractyl Health during the 3rd quarter valued at about $31,000. Jump Financial LLC purchased a new stake in shares of Fractyl Health during the 4th quarter valued at about $57,000. Scientech Research LLC acquired a new position in Fractyl Health during the 3rd quarter worth approximately $49,000. Finally, Prelude Capital Management LLC acquired a new position in Fractyl Health during the 3rd quarter worth approximately $55,000.

Fractyl Health Trading Up 3.9%

NASDAQ GUTS opened at $0.79 on Friday. The company has a market cap of $125.57 million, a P/E ratio of -0.61 and a beta of 2.29. Fractyl Health has a 12 month low of $0.38 and a 12 month high of $2.44. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The company has a 50-day moving average of $0.80 and a 200-day moving average of $0.91.

Fractyl Health (NASDAQ:GUTS) last released its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.23. As a group, equities analysts predict that Fractyl Health will post -0.6 earnings per share for the current year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.